Physician profile
James Collins
NPI 1306216205
$3,563.75
in general payments reported to CMS, 2019-2025
35 companies · $577 in 2025
The $577 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,139 · 2022: $638 · 2023: $458 · 2024: $753 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,787.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $417.69 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $407.26 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $302.25 | 2021-2024 | |
| Pfizer INC. | $298.09 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.82 | 2021-2025 | Synjardy, Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $250.35 | 2021-2025 | Trelegy Ellipta |
| Antares Pharma, INC. | $156.26 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.41 | 2021-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $120.30 | 2022-2025 | Farxiga, Airsupra |
| Paratek Pharmaceuticals, INC. | $114.39 | 2021 | |
| Sanofi-Aventis U.S. LLC | $101.24 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.72 | 2021-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $75.69 | 2021-2024 | Rexulti |
| Inspire Medical Systems, INC. | $68.85 | 2025 | Inspire |
| Olympus America INC. | $64.94 | 2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $58.93 | 2024-2025 | Voquezna |
| Electromed, INC. | $58.62 | 2021 | |
| Medtronic, INC. | $57.19 | 2024 | Interstim |
| Abiomed | $49.76 | 2022 | |
| Astellas Pharma US INC | $48.66 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.68 | 2022 | |
| Eisai INC. | $46.29 | 2021 | |
| Merck Sharp & Dohme LLC | $44.75 | 2021-2025 | Lagevrio |
| Abbott Laboratories | $44.23 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $39.93 | 2021 | |
| Exact Sciences Corporation | $36.22 | 2024 | Cologuard Collection Kit |
| Zimmer Biomet Holdings, INC. | $21.56 | 2023 | Gel-One Cross-Linked Hyaluronate |
| Tolmar, INC. | $19.58 | 2025 | Jatenzo |
| Verity Pharmaceuticals INC. | $18.86 | 2024 | Tlando |
| Amarin Pharma, INC. | $18.77 | 2021 | |
| Hologic Sales and Service, LLC | $17.20 | 2021 | |
| Jazz Pharmaceuticals INC. | $15.68 | 2022 | |
| Axsome Therapeutics, INC. | $15.07 | 2023 | Auvelity |
| Acella Pharmaceuticals, LLC | $14.49 | 2025 | NP Thyroid 60 |
| Janssen Pharmaceuticals, INC | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.